Aspirin in the Prevention of Cardiovascular Disease and Cancer

Annual Review of Medicine - Tập 72 Số 1 - Trang 473-495 - 2021
Emanuela Ricciotti1,2, Garret A. FitzGerald3,1,2
1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
2Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
3Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA

Tóm tắt

More than a century after its synthesis, daily aspirin, given at a low dose, is a milestone treatment for the secondary prevention of cardiovascular disease (CVD). Its role in primary prevention of CVD is still debated. Older randomized controlled trials showed that aspirin reduced the low incidence of myocardial infarction but correspondingly increased the low incidence of serious gastrointestinal bleeds without altering mortality. More recent trials see the benefit attenuated, perhaps obscured by other cardioprotective practices, while the bleeding risk remains, especially in older patients. Indirect evidence, both preclinical and clinical, suggests that aspirin may protect against sporadic colorectal cancer and perhaps other cancers. However, further studies are still necessary to warrant the consumption of aspirin for primary prevention of CVD and cancer by apparently healthy individuals.

Từ khóa


Tài liệu tham khảo

10.1146/annurev.biochem.69.1.145

10.1056/NEJM199110173251605

Patrignani P, 1983, Adv. Prostaglandin Thromboxane Leukotriene Res., 11, 259, 10.1016/0262-1746(83)90039-2

10.1016/S0140-6736(09)60503-1

10.1038/s41569-019-0225-y

10.1056/NEJMoa1804988

10.1056/NEJMoa1803955

10.1056/NEJMoa1800722

10.1056/NEJMoa1805819

10.1016/S0140-6736(18)31924-X

10.1016/j.jacc.2016.05.083

10.1080/09537104.2018.1492105

10.1053/j.gastro.2019.06.047

10.1038/bjc.2011.289

10.1016/j.ejphar.2019.172762

10.1016/j.vph.2018.10.008

10.1016/0006-2952(88)90729-0

10.1038/newbio231232a0

10.1056/NEJM198411083111902

10.1038/nsb0895-637

10.1021/acs.biochem.5b01378

10.1007/s11886-016-0702-4

10.1111/j.1538-7836.2009.03391.x

Brunton LL, Hilal-Dandan R, Knollman BC, eds. 2018. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill. 13th ed.

10.1001/jama.2012.5034

10.1007/s40264-016-0421-1

10.1111/j.1751-7141.2009.00058.x

10.1111/j.1538-7836.2012.04723.x

10.1182/blood-2009-08-236679

10.1161/01.CIR.72.6.1164

10.1161/CIRCINTERVENTIONS.110.960187

10.1182/blood.2019004596

10.1038/s41408-017-0041-8

10.1038/s41408-018-0078-3

10.1016/S0140-6736(18)31133-4

10.1136/bmj.1.5905.436

Coronary Drug Proj. Res. Group, 1980, Circulation, 62, V59

Breddin K, 1980, Circulation, 62, V63

10.1016/S0140-6736(79)92808-3

10.1001/jama.1980.03300330019023

10.1161/01.CIR.62.3.449

Lancet, 1980, Lancet, 1, 1172

10.1056/NEJM198308183090703

10.1056/NEJM198511283132201

10.1055/s-0038-1645038

10.1161/01.CIR.77.1.142

10.1161/01.CIR.80.6.1718

10.1016/0002-8703(92)90491-D

10.1161/01.RES.65.1.83

ISIS-2 (Second International Study of Infarct Survival) Collab. Group, 1988, Lancet, 2, 349

10.1055/s-0039-1687188

10.1136/bmj.296.6618.316

Reuther R, 1980, Munch. Med. Wochenschr., 122, 795

10.1056/NEJM197807132990201

Guiraud-Chaumeil B, 1982, Rev. Neurol., 138, 367

10.1161/01.STR.14.1.5

10.1161/01.STR.14.1.15

High-dose acetylsalicylic acid after cerebral infarction, 1987, Stroke, 18, 325, 10.1161/01.STR.18.2.325

10.1161/01.STR.19.10.1211

10.1016/0140-6736(91)92233-R

10.1056/NEJM199110313251801

Breddin K, 1980, Haemostasis, 9, 325

10.1136/bmj.308.6921.81

10.1136/bmj.324.7329.71

Smith SC, 2011, J. Am. Coll. Cardiol., 58, 2432, 10.1016/j.jacc.2011.10.824

10.1161/STR.0000000000000024

Piepoli MF, 2016, Eur. Heart J., 37, 2315, 10.1093/eurheartj/ehw106

10.1136/bmj.296.6618.313

10.1056/NEJM198907203210301

10.1001/jama.1992.03490100090033

10.1016/S0140-6736(98)04311-6

10.1136/bmj.a1840

10.1001/jama.2008.623

10.1007/s10557-018-6802-1

10.1001/jama.2010.221

10.1016/S0140-6736(97)11475-1

10.1016/S0140-6736(00)03539-X

10.1001/jama.2014.15690

10.1056/NEJMoa050613

10.1073/pnas.1406997111

10.1182/blood.V69.1.180.180

Am. Diabetes Assoc, 2019, Standards of Medical Care in Diabetes—2019. Diabetes Care, 42, S103

10.1016/j.jacc.2019.03.009

10.1001/jama.295.3.306

10.7326/M15-2113

10.7326/M15-2112

10.1093/eurheartj/ehy813

10.1001/jama.2018.20578

10.1016/j.jacc.2019.03.501

10.1378/chest.11-2306

10.1093/eurheartj/ehs092

10.7326/M16-0577

10.1093/eurheartj/ehz486

Arnett DK, 2019, Circulation, 140, e596

10.1016/j.jacc.2014.03.049

10.1001/jama.2019.8388

10.1093/eurheartj/ehz223

10.20452/pamw.15215

10.1161/CIRCULATIONAHA.116.023164

10.1053/j.gastro.2019.04.041

10.1016/S2468-1253(18)30037-2

10.1016/S0140-6736(17)30770-5

10.1016/j.gie.2014.03.024

10.1007/s00535-015-1055-2

10.1016/j.amjmed.2011.01.007

10.1038/ajg.2012.179

10.1056/NEJMoa1704559

10.1016/j.ajog.2017.11.561

10.1056/NEJM197712082972302

10.1177/230949901202000315

10.1016/j.arth.2018.03.001

10.1056/NEJMoa1114238

10.1111/jgs.14883

10.2337/dc19-1188

10.1212/WNL.0000000000009277

10.1016/S0140-6736(11)61720-0

10.1053/j.gastro.2007.09.035

10.1016/S0140-6736(10)62110-1

10.1016/S0140-6736(10)61543-7

10.1016/j.annonc.2020.02.012

10.1371/journal.pone.0057578

10.1158/1940-6207.CAPR-11-0106

10.1002/cam4.46

10.1056/NEJMoa0801297

10.1016/S0140-6736(11)61049-0

10.1016/S0140-6736(20)30366-4

10.7326/0003-4819-159-2-201307160-00002

10.7326/M15-2117

10.1038/bjc.2014.271

10.1053/j.gastro.2014.04.001

Bromham N, 2020, BMJ Clin. Res. Ed., 368, m461

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 72 Số 1

473-495

Thông tin tác giả